GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Current Deferred Revenue

BOLD (Boundless Bio) Current Deferred Revenue : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Boundless Bio's current deferred revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Boundless Bio Current Deferred Revenue Historical Data

The historical data trend for Boundless Bio's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Current Deferred Revenue Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Current Deferred Revenue
- - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Boundless Bio Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Boundless Bio Business Description

Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.